Immunotherapy for Liver Cancer
Physician-evaluated NK cell immunotherapy for patients diagnosed with Liver Cancer - at any stage.
Liver Cancer: Overview
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and frequently arises in the setting of underlying liver disease such as cirrhosis or chronic viral hepatitis. Treatment options include surgical resection, ablation, transarterial chemoembolization (TACE), systemic targeted therapy, and checkpoint immunotherapy in selected cases. HCC remains a challenging malignancy with limited treatment options in advanced stages.
NK Cell Immunotherapy Consideration
The liver contains a unique NK cell population as part of its innate immune system, and NK cell activity in HCC has been studied in the context of tumor immune evasion mechanisms. Research has explored NK cell-based approaches for hepatocellular carcinoma, recognizing the liver as an immunologically active organ. Eligibility for our program in liver cancer cases requires careful assessment of underlying liver function, as this is a primary determinant of treatment tolerability.
Hepatocellular carcinoma (HCC) and other primary liver cancers
Liver function assessment (Child-Pugh score) required as part of review
Cases evaluated for underlying cirrhosis, viral hepatitis, or other liver disease
Patients who have received or who declined TACE, sorafenib, or immunotherapy
Review includes full abdominal imaging and liver function parameters
Not all liver cancer patients qualify for our program. Eligibility is determined individually through physician-led medical review. These pages provide general educational context — not medical advice or a determination of suitability.
Next Step: Medical Review
If you or a family member has been diagnosed with breast cancer and is exploring additional options, the first step is to submit your case for physician review. Our team will assess your specific situation and respond with an eligibility determination.